Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2010

01-01-2010 | Letter to the Editor

Controversial BRCA1 allelotypes in commonly used breast cancer cell lines

Authors: Sivasundaram Karnan, Morassa Mohseni, Yuko Konishi, Akina Tamaki, Yoshitaka Hosokawa, Ben H. Park, Hiroyuki Konishi

Published in: Breast Cancer Research and Treatment | Issue 1/2010

Login to get access

Excerpt

To the editor: …
Appendix
Available only for authorised users
Literature
1.
Favy DA, Rio P, Maurizis JC et al (1999) Prolactin-dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem Biophys Res Commun 258(2):284–291CrossRefPubMed
2.
Abbott DW, Thompson ME, Robinson-Benion C et al (1999) BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 274(26):18808–18812CrossRefPubMed
3.
Chai Y, Chipitsyna G, Cui J et al (2001) c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene 20(11):1357–1367CrossRefPubMed
4.
Trenz K, Landgraf J, Speit G (2003) Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation. Breast Cancer Res Treat 78(1):69–79CrossRefPubMed
5.
Kroupis C, Stathopoulou A, Zygalaki E et al (2005) Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCA1 mRNA. Clin Biochem 38(1):50–57CrossRefPubMed
6.
El-Tanani MK, Campbell FC, Crowe P et al (2006) BRCA1 suppresses osteopontin-mediated breast cancer. J Biol Chem 281(36):26587–26601CrossRefPubMed
7.
Cousineau I, Belmaaza A (2007) BRCA1 haploinsufficiency, but not heterozygosity for a BRCA1-truncating mutation, deregulates homologous recombination. Cell Cycle 6(8):962–971PubMed
8.
Francisco DC, Peddi P, Hair JM et al (2008) Induction and processing of complex DNA damage in human breast cancer cells MCF-7 and nonmalignant MCF-10A cells. Free Radic Biol Med 44(4):558–569CrossRefPubMed
9.
Yu X, Luo Y, Zhou Y et al (2008) BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4–p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. Int J Oncol 33(3):555–563PubMed
10.
Holt JT, Thompson ME, Szabo C et al (1996) Growth retardation and tumour inhibition by BRCA1. Nat Genet 12(3):298–302CrossRefPubMed
11.
Kytola S, Rummukainen J, Nordgren A et al (2000) Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping. Genes Chromosomes Cancer 28(3):308–317CrossRefPubMed
12.
Davidson JM, Gorringe KL, Chin SF et al (2000) Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer 83(10):1309–1317CrossRefPubMed
13.
Roschke AV, Tonon G, Gehlhaus KS et al (2003) Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 63(24):8634–8647PubMed
Metadata
Title
Controversial BRCA1 allelotypes in commonly used breast cancer cell lines
Authors
Sivasundaram Karnan
Morassa Mohseni
Yuko Konishi
Akina Tamaki
Yoshitaka Hosokawa
Ben H. Park
Hiroyuki Konishi
Publication date
01-01-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0465-3

Other articles of this Issue 1/2010

Breast Cancer Research and Treatment 1/2010 Go to the issue

Review

Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence

Preclinical Study

Expression of Gli1 correlates with the transition of breast cancer cells to estrogen-independent growth

Epidemiology

Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers

Clinical trial

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Epidemiology

The impact of sociodemographic, treatment, and work support on missed work after breast cancer diagnosis

Epidemiology

Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits